Dr. Bazhenova on Ongoing Clinical Trials With Immunotherapy in NSCLC

Video

Lyudmila A. Bazhenova, MD, discusses ongoing clinical trials in non–small cell lung cancer that are investigating the utility of immunotherapy.

Lyudmila A. Bazhenova, MD, medical oncologist and professor of clinical medicine at University of California, San Diego, discusses ongoing clinical trials in non—small cell lung cancer (NSCLC) that are investigating the utility of immunotherapy.

Several ongoing studies are examining the role of immunotherapy after surgical resection, says Bazhenova. For example, an ALCHEMIST study is randomizing patients to nivolumab (Opdivo) versus placebo after they complete surgical resection and standard adjuvant therapy; the study is still ongoing.

Some pharmaceutical-sponsored trials that are very similar in design are also ongoing; these trials are examining the addition of immunotherapy to patients who received curative therapy for early stage lung cancer, concludes Bazhenova.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,